triagonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-13. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
==== Other materials ==== Paraffin wax does not always provide a sufficiently hard matrix for cutting very thin sections (which are especially important for electron microscopy). Paraffin wax may also be too soft in relation to the tissue, the heat of the melted wax may alter the tissue in undesirable ways, or the dehydrating or clearing chemicals may harm the tissue. Alternatives to paraffin wax include, epoxy, acrylic, agar, gelatin, celloidin, and other types of waxes. In electron microscopy epoxy resins are the most commonly employed embedding media, but acrylic resins are also used, particularly where immunohistochemistry is required. For tissues to be cut in a frozen state, tissues are placed in a water-based embedding medium. Pre-frozen tissues are placed into molds with the liquid embedding material, usually a water-based glycol, OCT, TBS, Cryogen, or resin, which is then frozen to form hardened blocks.
Shafts were drilled at the site before the test in order to accelerate sample collection after explosion, so that explosion would expel radioactive material from the epicenter through the shafts and to collecting volumes near the surface. This method was tried in two tests and instantly provided hundreds of kilograms of material, but with actinide concentration three times lower than in samples obtained after drilling. Whereas such method could have been efficient in scientific studies of short-lived isotopes, it could not improve the overall collection efficiency of the produced actinides. Though no new elements (except einsteinium and fermium) could be detected in the nuclear test debris, and the total yields of transuranics were disappointingly low, these tests did provide significantly higher amounts of rare heavy isotopes than previously available in laboratories.
== Candidacy relating to elections of the German Federal president == At the 2010 election for the German Federal President, Kermani served as a member of the 14th Federal Assembly at the recommendation of the Green Party of Hessen. And in 2017, Kermani was mentioned as a potential candidate for German Federal President in that year's federal presidential election. According to a report in Der Spiegel, then-SPD chairman Sigmar Gabriel, in cooperation with other parties, had intended to nominate Kermani to run for Federal President. However, the plan failed due to resistance from the Greens. In particular, Kermani was rejected by the Realos wing of the Green Party, because the Realos were aiming to form a Black-Green coalition (i.e. a coalition with the Christian Democrats) subsequent to the general federal elections and thus did not want to be seen as endorsing a Red-Red-Green (i.e. Social Democratic, Left Party and Green Party) coalition.
== External links == WHO Good Clinical Laboratory Practice (GCLP) (11 Oct 2010) MHRA guidance on the maintenance of regulatory compliance in laboratories that perform the analysis or evaluation of clinical trial samples (11 Oct 2010)
Sources: en.wikipedia.org
Small cell lung carcinoma accounts for 15% of lung cancers in the United States. Small cell lung cancer occurs almost exclusively in smokers – most commonly in heavy smokers and rarely in non-smokers.
In April 2025, Hegseth issued a directive to the secretary of the Army ordering on a sweeping overhaul, prioritizing defending the homeland and deterring China in the Indo-Pacific. Among others, the directive instructing a consolidated budget lines in unmanned systems, counter-drone systems and electronic warfare, force structure changes and expanded use of other transaction agreements. The directive also instructed to downsize or close redundant headquarters as well as merging Army Futures Command and Training and Doctrine Command, and merging four-star headquarters Army Forces Command with Army North and Army South into a single headquarters focused on homeland defense as well as the elimination of at least 20% of four-star general positions to enhance efficiency and operational effectiveness. Hegseth also signed a memorandum to reduce the Department of Defense's civilian workforce, aiming to eliminate duplicative efforts and excessive bureaucracy. The initiative includes offering voluntary early retirement and deferred resignation programs to incentivize top performers and enhance efficiency. That month, Hegseth received criticism from some Senate Democrats over alleged civilian deaths in the Yemen strikes.
==== Other countries ==== Usually, the availability of oxandrolone is quite limited. It is no longer available in Europe. Oxandrolone is available in some less-regulated markets in Asia such as Malaysia and in Mexico. Historically, oxandrolone has been marketed in Argentina, Australia, Brazil, France, Italy, Japan, and Spain, but it appears to no longer be available in these countries.
Interestingly, relocalization of eIF4E from the nucleus to the cytoplasm correlated with clinical remissions indicative of the relevance of its nuclear activities to disease progression. Subsequent ribavirin trials in AML in combination with antileukemic drugs again showed objective clinical responses including remissions and molecular targeting of eIF4E. Clinical responses correlated with reduced nuclear eIF4E and clinical relapse with re-emergence of eIF4E nuclear eIF4E and its RNA export activity in these AML studies. Other studies used ribavirin in combination showed similar promising results in head and neck cancer. Ribavirin impairs all of the activities of eIF4E examined to date (splicing, capping, RNA export and translation). Thus, eIF4E has been successfully therapeutically targetable in humans; however drug resistance to ribavirin is an emergent problem to long term disease control. eIF4E has also been targeted by antisense oligonucleotides which were very potent in mouse models of prostate cancer, but in monotherapy trials in humans did not provide clinical benefit likely due to the inefficiency of reducing eIF4E levels in humans compared to mice. Recent improvements in nanoparticle delivery may improve this strategy. There is also an allosteric inhibitor of eIF4E which binds between the cap-binding site and the dorsal surface that is used experimentally.
When initially discovered, some scientists proposed that Osedax was a whale-bone specialist, a notion later disproven by the discovery of Osedax on a variety of skeletal substrates including bone fragments, teleost bones, shark teeth, reptile and bird skeletons, pinniped bones, experimentally placed cow bones, and even human remains. Multiple species of Osedax can co-exist in close proximity, even on the same bone. Osedax and their borings enhance local biodiversity by dissolving the tough external cortical bone and tunneling through their internal layers, increasing structural complexity and providing new regions for microfauna to colonize. As such, Osedax are considered ecosystem engineers. However, these borings compromise the structural integrity of the bones, causing them to collapse after extensive boring, rendering these new habitats temporary. The role of Osedax in the degradation of marine vertebrate remains is important to marine vertebrate taphonomy.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.